Following OraSure's November 2024 lawsuit accusing NowDx of misappropriating trade secrets, NowDx has countersued OraSure over similar allegations.

The company received conditional approval from New York State for its new systemic lupus erythematosus and rheumatoid arthritis biomarker assays.

Last week, readers were most interested in a story about the progress made by test developers toward commercializing rapid tests for sepsis.

Numerous firms reported preliminary revenues along with other business updates on Sunday and Monday ahead of the annual JP Morgan Healthcare Conference.

The rapid spinning disk-based immunoassay technology will enhance BioMérieux's offering at the point of care, the firm said.

Rounding out the other four largest financing rounds in 2024 are proteomics company Alamar Biosciences' $128 million Series C ...

Biomy has developed its DeepPathFinder digital pathology platform to analyze images to classify cell and tissue types in specific regions.

The chemiluminescence-based immunoassay is used for the direct quantitative measurement of free testosterone in serum or plasma, with results in 48 minutes.

NEW YORK – After two years of decline in 2022 and 2023, the 360Dx Top 30 rebounded in 2024, rising 4 percent year over year.

The funding will be used to move the ARGO-HT research platform into an FDA-cleared system to support the development of diagnostic tests.